1. Home
  2. JANX vs REF Comparison

JANX vs REF Comparison

Compare JANX & REF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

N/A

Current Price

$10.13

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Reformation Inc. Common Stock

REF

Reformation Inc. Common Stock

N/A

Current Price

$18.45

Market Cap

1.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
JANX
REF
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
JANX
REF
Price
$10.13
$18.45
Analyst Decision
Buy
Strong Buy
Analyst Count
18
9
Target Price
★ $33.14
$20.50
AVG Volume (30 Days)
★ 946.4K
518.5K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $10,000,000.00
N/A
Revenue This Year
$174.21
$20.57
Revenue Next Year
N/A
$16.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$10.16
$11.85
52 Week High
$35.34
$20.57

Technical Indicators

Market Signals
Indicator
JANX
REF
Relative Strength Index (RSI) 25.34 56.24
Support Level N/A $12.55
Resistance Level $14.47 $20.55
Average True Range (ATR) 1.16 1.48
MACD -0.48 -0.01
Stochastic Oscillator 0.33 55.93

Price Performance

Historical Comparison
JANX
REF

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About REF Reformation Inc. Common Stock

Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.

Share on Social Networks: